Login to Your Account



Clinic Roundup


Wednesday, June 26, 2013
• Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., said the Sarah Cannon Research Institute in Nashville opened enrollment in a Phase I study testing MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small-cell lung cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription